genedrive Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

genedrive şirketinin toplam hissedar öz sermayesi £1.5M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £3.4M ve £1.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£1.23m
Eşitlik	UK£1.51m
Toplam yükümlülükler	UK£1.93m
Toplam varlıklar	UK£3.44m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: D6M 'nin kısa vadeli varlıkları ( £3.2M ) kısa vadeli yükümlülüklerini ( £1.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: D6M un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: D6M borçsuzdur.

Borcun Azaltılması: D6M şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: D6M şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: D6M tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

genedrive Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

genedrive plc to Report Fiscal Year 2024 Results on Nov 29, 2024

genedrive plc Announces Successful Funding Award to Its Clinical Partners from the National Institute for Health and Care Research in Collaboration with the UK Government Office for Life Sciences

New minor risk - Financial data availability

Genedrive plc Announces CEO Changes

Genedrive plc Receives Breakthrough Device Designation from the U.S. Food and Drug Administration

genedrive plc has completed a Follow-on Equity Offering in the amount of £6 million.

genedrive plc has filed a Follow-on Equity Offering in the amount of £3.5 million.

New major risk - Shareholder dilution

genedrive plc to Report First Half, 2024 Results on Mar 28, 2024

New major risk - Market cap size

genedrive plc, Annual General Meeting, Dec 29, 2023

Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.055 loss in FY 2022)

New major risk - Market cap size

genedrive plc to Report Fiscal Year 2023 Results on Nov 30, 2023

New minor risk - Financial data availability

genedrive plc Announces Chief Executive Officer Changes

Genedrive plc Achieves UKCA Marking Registration for its New Genedrive CYP2C19 System

genedrive plc, Annual General Meeting, Dec 29, 2022

Full year 2022 earnings released: UK£0.055 loss per share (vs UK£0.012 loss in FY 2021)

genedrive plc to Report Fiscal Year 2022 Results on Nov 21, 2022

genedrive plc Files US FDA Pre-Submission for the Genedrive® MT-RNR1 Product Range

Genedrive plc Announces UK's National Institute for Health and Clinical Excellence Commences an Evaluation of CYP2C19 Genotype Testing for Clopidogrel Treatment

NICE to Evaluate the Genedrive MT-RNR1 Test

High number of new directors

Genedrive plc Announces Point-Of-Care Cov19-Id Kit Receives CTDA Approval from Medicines and Healthcare Products Regulatory Agency

High number of new directors

Now 24% undervalued

First half 2022 earnings released

Genedrive plc Announces NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test

genedrive plc Announces Resignation of Matthew Fowler as Group's Chief Financial Officer

Genedrive plc Provides Update on Point of Care Covid Test

genedrive plc to Report First Half, 2022 Results on Mar 29, 2022

genedrive plc Announces UK CTDA application for Point-of-Care Genedrive®?COV19-ID kit

Full year 2021 earnings released: UK£0.012 loss per share (vs UK£0.55 loss in FY 2020)

Insufficient new directors

Genedrive COVID-19 Point of Care device update

First half 2021 earnings released: EPS UK£0.019 (vs UK£0.089 loss in 1H 2020)

genedrive plc Enters Distribution Agreement with Mountain Horse Solutions

genedrive plc Provides an Update on its Antibiotic Induced Hearing Loss Assay

New 90-day high: €1.05

genedrive plc Enters into Distribution Agreement with Beckman Coulter Life Sciences

genedrive plc to Report First Half, 2021 Results on Mar 25, 2021

New 90-day low: €0.32

genedrive plc, Annual General Meeting, Dec 30, 2020

New 90-day low: €0.37

Genedrive plc Announces Successful Completion of the Antibiotic Induced Hearing Loss Implementation Study

Revenue misses expectations

Full year 2020 earnings released: UK£0.55 loss per share

Genedrive Announces HCV ID Kit Demonstrates High Clinical Accuracy in India Study

Full year 2020 earnings released: UK£0.55 loss per share

Revenue misses expectations

New 90-day low: €0.71

genedrive plc to Report Fiscal Year 2020 Results on Nov 17, 2020

genedrive plc Announces South African Approval

genedrive plc Announces Completes Initial Testing of Beckman Coulter Life Sciences' Rnadvance Viral RNA

New 90-day high: €1.48

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin